18F-氟雌二醇PET/CT预测雌激素受体阳性乳腺癌患者内分泌治疗获益:系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究、308例基线接受18F-FES PET/CT后行内分泌治疗的ER阳性乳腺癌患者,采用随机效应模型合并分析。18F-FES阳性者临床获益可能性为66%(95%CI 51%-79%),阴性者为11%(95%CI 3.5%-22%),阳性较阴性的获益风险比为3.21(95%CI 1.96-5.25,P<0.0001)。作者认为18F-FES PET是预测内分泌治疗成功可能性的生物标志物。
要点
- 18F-FES阳性者内分泌治疗临床获益可能性66%(95%CI 51%-79%),阴性者11%(95%CI 3.5%-22%)。
- 18F-FES阳性较阴性者的临床获益风险比为3.21(95%CI 1.96-5.25,P<0.0001)。
- 18F-FES阴性者虽病理ER阳性,仍不太可能从内分泌治疗中获益。
核心结论
- 18F-FES PET是预测ER阳性乳腺癌患者内分泌治疗成功可能性的有效生物标志物。
- 有强证据表明18F-FES阴性者尽管病理为ER阳性,仍不太可能从内分泌治疗中获得临床获益。
- 这支持18F-FES PET用于识别内分泌治疗可能适合或不适合的患者。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、MEDLINE via OVID、Embase、Web of Science、Emcare和Cochrane Central Register of Controlled Trials至2024年11月1日。
- 纳入基线接受18F-FES PET/CT并随后接受内分泌治疗的ER阳性乳腺癌患者研究。
- 从1,105条数据库记录中纳入12项研究进行荟萃分析,共308例参与者有18F-FES PET结果与内分泌治疗反应数据。
- 采用随机效应模型估计阳性及阴性18F-FES PET后内分泌治疗临床获益可能性及阳性较阴性的风险比。
主要发现
- 18F-FES阳性后临床获益可能性为66%(95%CI 51%-79%;I²=76.6%;n=227例参与者)。
- 18F-FES阴性后临床获益可能性为11%(95%CI 3.5%-22%;I²=0.0%;n=81例参与者)。
- 18F-FES阳性较阴性者的获益风险比为3.21(95%CI 1.96-5.25;I²=0.0%;P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 18F-FES阳性后临床获益可能性的合并估计异质性I²=76.6%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-fluoroestradiol (18F-FES) PET/CT has been investigated as a potential biomarker to predict response to endocrine therapies in patients with estrogen receptor (ER)-positive breast cancer. Although previous findings were promising, most had limited statistical significance because of small individual sample sizes. Therefore, we performed a systematic review and metaanalysis of the 18F-FES PET/CT literature to increase our power to evaluate the utility of 18F-FES PET/CT as a biomarker for prediction of clinical benefit from endocrine therapy in patients with ER-positive breast cancer. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, MEDLINE via OVID, Embase, Web of Science, Emcare, and the Cochrane Central Register of Controlled Trials through November 1, 2024, for studies that included patients with ER-positive breast cancer who received an 18F-FES PET/CT at baseline and received subsequent endocrine therapy. For each eligible study, data were extracted using a predesigned data extraction form. Random effects models were used to estimate the likelihood of clinical benefit from endocrine therapy after a positive 18F-FES PET scan, the likelihood of clinical benefit from endocrine therapy after a negative 18F-FES PET scan, and the risk ratio of clinical benefit from endocrine therapy comparing those who were 18F-FES-positive to those who were 18F-FES-negative. Results: From 1,105 database records retrieved, 12 studies were included in the metaanalysis (n = 308 participants with data on 18F-FES PET results and response to endocrine therapy). The likelihood of clinical benefit after a positive 18F-FES PET scan was 66% (95% CI, 51%-79%; I 2 = 76.6%; n = 227 participants) and the likelihood after a negative 18F-FES PET scan was 11% (95% CI, 3.5%-22%; I 2 = 0.0%; n = 81 participants). The risk ratio of response that compared those who were 18F-FES-positive with those who were 18F-FES-negative was 3.21 (95% CI, 1.96-5.25; I 2 = 0.0%; P < 0.0001). Conclusion: 18F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive breast cancer. There is strong evidence that patients with 18F-FES-negative disease are unlikely to derive clinical benefit from endocrine therapies, despite the presence of ER-positive disease on pathology. This supports a role for 18F-FES PET in identifying patients for whom endocrine therapy may or may not be an appropriate treatment option.
引用
- Parihar AS, Vaz S, Sutcliffe S, et al. 18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2025. PMID: 40081952. doi:10.2967/jnumed.124.269163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。